Comorbilidades em Doentes com Psoríase: Revisitar as Antigas, Reconhecer as Emergentes

Yeung H, Takeshita J, Mehta NN, Lim HW, Elmets CA,

Feldman SR, et al. Psoriasis severity and the prevalence

of major medical comorbidity. JAMA Dermatol. 2013;

:1173-9.

Strauss H. Zur Lehre von der neurogenen und der

thyreogenen Glykosurie. Dtsch Med Wochenschr. 1897;

:309-12.

Reed WB, Becker SW, Rohde R, Heiskell CL . Psoriasis

and arthritis. Clinicopathologic study. Arch Dermatol.

; 83:541-8.

McDonald CJ, Calabresi P. Occlusive vascular disease in

psoriatic patients. N Engl J Med. 1973; 288:912.

Torres T, Machado S, Mendonc¸a D, Selores M.

Cardiovascular comorbidities in childhood psoriasis. Eur

J Dermatol. 2014; 24:229-35.

Kimball AB, Szapary P, Mrowietz U, Reich K, Langley

RG, You Y, et al. Underdiagnosis and undertreatment of

cardiovascular risk factors in patients with moderate to

severe psoriasis. J Am Acad Dermatol. 2012; 67:76-85.

Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The

prevalence and odds of depressive symptoms and

clinical depression in psoriasis patients: a systematic

review and meta-analysis. J Invest Dermatol. 2014;

:1542-51.

Roque Ferreira B, Santiago L, Simões J, Ramos L, Brites

M, Reis J, et al. Psoríase, psicofármacos e comorbilidades

psiquiátricas: um estudo de caso-controlo numa

população de doentes hospitalizados. Rev Soc Port

Dermatol Venereol. 2017; 75:43-8.

Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated

with ulcerative colitis and Crohn’s disease. J Eur Acad

Dermatol Venereol. 2009; 23:561-5.

Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N,

Méndez-Sánchez N, Arrese M. Risk of non-alcoholic

fatty liver disease in patients with psoriasis: a systematic

review and meta-analysis. J Eur Acad Dermatol Venereol.

; 29:656-62.

Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A,

Van Voorhees AS, et al. Psoriasis and comorbid diseases:

Epidemiology. J Am Acad Dermatol. 2017; 76:377-90.

Wu JJ, Poon KY, Channual JC, Shen AY. Association

between tumor necrosis factor inhibitor therapy and

myocardial infarction risk in patients with psoriasis. Arch

Dermatol. 2012; 148:1244-50.

Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen

SL, Iversen L, et al. Cardiovascular disease event rates in

patients with severe psoriasis treated with systemic antiinflammatory

drugs: a Danish real-world cohort study. J

Intern Med. 2013; 273:197-204.

Abuabara K, Lee H, Kimball AB. The effect of systemic

psoriasis therapies on the incidence of myocardial

infarction: a cohort study. Br J Dermatol. 2011;

:1066-73.

Chen YJ, Chang YT, Shen JL, Chen TT, Wang CB, Chen

CM, et al. Association between systemic antipsoriatic

drugs and cardiovascular risk in patients with psoriasis

with or without psoriatic arthritis: a nationwide cohort

study. Arthritis Rheum. 2012; 64:1879-87.

Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular

disease event rates in patients with severe psoriasis

treated with systemic anti-inflammatory drugs: a Danish

real-world cohort study. J Intern Med. 2013;273:197-

Abuabara K, Lee H, Kimball AB. The effect of systemic

psoriasis therapies on the incidence of myocardial

infarction: a cohort study. Br J Dermatol. 2011;165:1066-